Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients.
Raffaele OrnelloFayyaz AhmedAndrea NegroAnna Maria MiscioAntonio SantoroAlicia AlpuenteAntonio RussoMarcello SilvestroSabina CevoliNicoletta BrunelliFabrizio VernieriLicia GrazziBaraldi CarloSimona GuerzoniAnna P AndreouGiorgio LambruKatharina KammRuth RuscheweyhMarco RussoPaola TorelliElena FilatovaNina V LatyshevaAnna Gryglas-DworakMarcin StraburzyńskiCalogera ButeraBruno ColomboMassimo FilippiPatricia Pozo-RosichPaolo MartellettiSimona SaccoPublished in: Pain and therapy (2021)
Our pooled analysis suggests that the response to BT-A is significant in both men and women with a small gender difference in favor of women. Men tended to stop the treatment more frequently than women. We emphasize the need for more gender-specific data on migraine treatments from randomized controlled trials and observational studies.
Keyphrases
- polycystic ovary syndrome
- end stage renal disease
- mental health
- randomized controlled trial
- ejection fraction
- newly diagnosed
- pregnancy outcomes
- peritoneal dialysis
- middle aged
- prognostic factors
- type diabetes
- systematic review
- pregnant women
- insulin resistance
- big data
- metabolic syndrome
- combination therapy
- artificial intelligence
- study protocol
- patient reported